A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients

AGOURA HILLS, Calif., March 2, 2022 /PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical data related to its proprietary Tmod™ cell therapy platform have been published in Science...

Click to view original post